These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 28648033)

  • 1. [Update on the clinical application of valsartan/sacubitril in patients with heart failure].
    Zhonghua Xin Xue Guan Bing Za Zhi; 2017 Jun; 45(6):538-541. PubMed ID: 28648033
    [No Abstract]   [Full Text] [Related]  

  • 2. Estimating the Long-Term Treatment Benefits of Sacubitril-Valsartan.
    Claggett B; Packer M; McMurray JJ; Swedberg K; Rouleau J; Zile MR; Jhund P; Lefkowitz M; Shi V; Solomon SD;
    N Engl J Med; 2015 Dec; 373(23):2289-90. PubMed ID: 26630151
    [No Abstract]   [Full Text] [Related]  

  • 3. Characteristics of early sacubitril/valsartan patients and considerations for studies in electronic health record data.
    Gagne JJ; Tsacogianis T; Bruce Wirta S; Rogers JR; Calado F; Chang CL; Turner SJ; Schlienger RG; Balas B; Abdurrob A; Najafzadeh M; Wang SV
    J Comp Eff Res; 2018 Nov; 7(11):1073-1082. PubMed ID: 30156128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neprilysin inhibition with sacubitril/valsartan in the treatment of heart failure: mortality bang for your buck.
    Ansara AJ; Kolanczyk DM; Koehler JM
    J Clin Pharm Ther; 2016 Apr; 41(2):119-27. PubMed ID: 26992459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adoption of Sacubitril/Valsartan for the Management of Patients With Heart Failure.
    Sangaralingham LR; Sangaralingham SJ; Shah ND; Yao X; Dunlay SM
    Circ Heart Fail; 2018 Feb; 11(2):e004302. PubMed ID: 29453287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
    Hubers SA; Brown NJ
    Circulation; 2016 Mar; 133(11):1115-24. PubMed ID: 26976916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Sacubitril-valsartan is a new cornerstone in heart failure therapy].
    Lund LH; Fu M; Swedberg K
    Lakartidningen; 2016 Jul; 113():. PubMed ID: 27434604
    [No Abstract]   [Full Text] [Related]  

  • 8. Sacubitril/Valsartan in Clinical Practice: The Italian Experience.
    Valle R; Aspromonte N
    Cardiology; 2017; 138 Suppl 1():1-2. PubMed ID: 29262406
    [No Abstract]   [Full Text] [Related]  

  • 9. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure.
    Velazquez EJ; Morrow DA; DeVore AD; Duffy CI; Ambrosy AP; McCague K; Rocha R; Braunwald E;
    N Engl J Med; 2019 Feb; 380(6):539-548. PubMed ID: 30415601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sacubitril/Valsartan: potential treatment for paediatric heart failure.
    Das BB; Scholl F; Vandale B; Chrisant M
    Cardiol Young; 2018 Sep; 28(9):1077-1081. PubMed ID: 29979147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sacubitril-Valsartan for the Treatment of Heart Failure: Effectiveness and Value.
    Ollendorf DA; Sandhu AT; Pearson SD
    JAMA Intern Med; 2016 Feb; 176(2):249-50. PubMed ID: 26720832
    [No Abstract]   [Full Text] [Related]  

  • 12. Sacubitril-valsartan: novel therapy for heart failure.
    Sehn E; McDonald T; Lindblad AJ
    Can Fam Physician; 2017 Sep; 63(9):697. PubMed ID: 28904036
    [No Abstract]   [Full Text] [Related]  

  • 13. Potential Uses of Sacubitril/Valsartan: Need for Data on Efficacy and Safety.
    Huet F; Akodad M; Kalmanovitch E; Adda J; Agullo A; Batistella P; Roubille C; Roubille F
    Am J Cardiovasc Drugs; 2019 Feb; 19(1):1-10. PubMed ID: 30345485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Diuretic Effect of Sacubitril/Valsartan Might Be Clinically Relevant.
    Beck-da-Silva L; Rohde LE
    Arq Bras Cardiol; 2019 Jul; 112(6):791-792. PubMed ID: 31314832
    [No Abstract]   [Full Text] [Related]  

  • 15. Sacubitril/Valsartan (Entresto): The Next Blockbuster Medication?
    Wachholtz CD; Hayes WJ
    S D Med; 2015 Nov; 68(11):510-1. PubMed ID: 26689034
    [No Abstract]   [Full Text] [Related]  

  • 16. [Experience of hospital initiation of sacubitril/valsartan in a female patient after acute decompensated heart failure].
    Galochkin SA; Lukina OI; Meraĭ IA; Villevalde SV; Kobalava ZD
    Kardiologiia; 2018 SMay; (S5):60-64. PubMed ID: 29894678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin Receptor Neprilysin Inhibitor Attenuates Myocardial Remodeling and Improves Infarct Perfusion in Experimental Heart Failure.
    Pfau D; Thorn SL; Zhang J; Mikush N; Renaud JM; Klein R; deKemp RA; Wu X; Hu X; Sinusas AJ; Young LH; Tirziu D
    Sci Rep; 2019 Apr; 9(1):5791. PubMed ID: 30962467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Sacubitril/valsartan receives European approval].
    MMW Fortschr Med; 2015 Dec; 157(21-22):84. PubMed ID: 26960881
    [No Abstract]   [Full Text] [Related]  

  • 19. Cost-effectiveness of sacubitril/valsartan in chronic heart-failure patients with reduced ejection fraction.
    Ademi Z; Pfeil AM; Hancock E; Trueman D; Haroun RH; Deschaseaux C; Schwenkglenks M
    Swiss Med Wkly; 2017; 147():w14533. PubMed ID: 29185253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mortality and Heart Failure Risk Reductions in Patients Treated With Sacubitril-Valsartan in Clinical Trials.
    Cordero A; Nuñez J; Bertomeu-González V; Fácila L; Quintanilla MA; Rodríguez-Mañero M; Escribano D; Valle A; de la Espriella R; Torres-Llergo J; Bayés-Genís A; González-Juanatey JR
    Am J Ther; 2022 Sep-Oct 01; 29(5):e572-e575. PubMed ID: 36074989
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.